Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

NCT01511783
View directory record Official record
Conditions
Healthy
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

NCT03087942
View directory record Official record
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 16, 2026, 3:43 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects

NCT01340183
View directory record Official record
Conditions
Healthy
Interventions
AZD5099, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

NCT01953341
View directory record Official record
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BG9928 in Subjects With Hepatic Impairment

NCT00858156
View directory record Official record
Conditions
Hepatic Impairment
Interventions
BG9928
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2495655 in Healthy Subjects

NCT01341470
View directory record Official record
Conditions
Healthy Volunteer
Interventions
LY2495655, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
24 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

NCT04908995
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral tablet, Placebo oral tablet
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

NCT01496677
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701 FA 200 mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

NCT02415439
View directory record Official record
Conditions
Healthy
Interventions
VBP15, Placebo
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

NCT04857957
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Oral dose CNTX-6016 or oral dose Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects

NCT02855177
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, PF-06427878
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Glendale, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

NCT03071770
View directory record Official record
Conditions
Healthy
Interventions
ivosidenib (AG-120)
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omnitram Pharmacokinetic Study In Healthy Volunteers

NCT02205554
View directory record Official record
Conditions
Pain
Interventions
Omnitram, Tramadol, Placebo
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01181427
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-267, Placebo, Blood Sample Collection, Cytochrome P450 inhibitor
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Waukegan, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

NCT04242953
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
SCO-120, matching placebo
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Dilworth, Minnesota • Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Second Study to Determine the Effect of GSK256073A on HVTs

NCT00551694
View directory record Official record
Conditions
Healthy Subjects, Dyslipidaemias
Interventions
GSK256073A tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

NCT04075175
View directory record Official record
Conditions
Diphtheria
Interventions
S315, 0.9% Sodium Chloride (NaCl)
Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

NCT02215941
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00912353
View directory record Official record
Conditions
Healthy
Interventions
AZD7268, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gelndale, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants

NCT04220801
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ZM-H1505R
Drug
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects

NCT07671833
View directory record Official record
Conditions
Healthy Participants
Interventions
LY03015 (LPM3770164 extended-release tablets)
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

NCT02871037
View directory record Official record
Conditions
Normal Healthy
Interventions
PF-05221304, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 16, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

NCT02089087
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CFZ533, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
5
States / cities
Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 16, 2026, 3:43 AM EDT